000 03731nam a22004335i 4500
001 978-1-59745-148-2
003 DE-He213
005 20161121230803.0
007 cr nn 008mamaa
008 100301s2007 xxu| s |||| 0|eng d
020 _a9781597451482
_9978-1-59745-148-2
024 7 _a10.1007/978-1-59745-148-2
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
245 1 0 _aDeoxynucleoside Analogs In Cancer Therapy
_h[electronic resource] /
_cedited by Godefridus J. Peters.
264 1 _aTotowa, NJ :
_bHumana Press,
_c2007.
300 _aXIV, 476 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCancer Drug Discovery and Development
505 0 _aNucleoside Transport Into Cells -- The Role of Deoxycytidine Kinase in DNA Synthesis and Nucleoside Analog Activation -- Deoxynucleoside Kinases and Their Potential Role in Deoxynucleoside Cytotoxicity -- Nucleotidases and Nucleoside Analog Cytotoxicity -- Pumping Out Drugs -- Cytosine Arabinoside -- Clofarabine -- L-Nucleosides as Chemotherapeutic Agents -- Troxacitabine (Troxatyl ™) -- 9-?-D-Arabinofuranosylguanine -- Gemcitabine -- Clinical Activity of Gemcitabine as a Single Agent and in Combination -- Nucleoside Radiosensitizers -- NONMEM Population Models of Cytosine Arabinoside and Fludarabine Phosphate in Pediatric Patients With Leukemia -- ThecycloSal-Nucleotide Delivery System -- Purine and Pyrimidine-Based Analogs and Suicide Gene Therapy -- 3?-Deoxy-3?-Fluorothymidine as a Tracer of Proliferation in Positron Emission Tomography.
520 _aEmerging as an important new volume in the renowned Cancer Drug Discovery and Development™ series, Deoxynucleoside Analogs in Cancer Therapy expertly summarizes the current status of development and application of deoxynucleoside analogs. Authoritative up-to-date reviews are presented by scientists well known in their specific areas and all contributions include valuable sound advice on structure and topics. Organized into several sections, the first part covers general aspects of drug uptake and metabolism and explains how novel technology has enabled a rapid expansion of this field. The second part is concerned with a number of specific drugs including cytarabine, gemcitabine, troxacitabine, clofarabine and Ara-G. The final section covers pharmacokinetics, prodrugs, and specific applications such as radiosensitization, gene therapy, and the use of deoxynucleoside analogs as tracers. Throughout Deoxynucleoside Analogs in Cancer Therapy, the focus is on novel aspects of deoxynucleoside analogs in the clinical context, as well as on unexpected targets of these compounds, such as their specific activity against cell cycle-dependent kinases or oncogenes. The wealth of information presented here can be used to design rational combinations aimed at inhibiting various cellular signaling pathways, or combining inhibition of various targets. Deoxynucleoside Analogs in Cancer Therapy has been designed specifically to facilitate such an interaction between various fields.
650 0 _aMedicine.
650 0 _aCancer research.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
700 1 _aPeters, Godefridus J.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781588293275
830 0 _aCancer Drug Discovery and Development
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-59745-148-2
912 _aZDB-2-SBL
950 _aBiomedical and Life Sciences (Springer-11642)
999 _c503954
_d503954